Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Weighted mean

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    140 result(s) found for: Weighted mean. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2014-000097-19 Sponsor Protocol Number: TRANCHE Start Date*: 2016-06-10
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinje...
    Medical condition: Food allergy
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002546-36 Sponsor Protocol Number: 2018-002546-36 Start Date*: 2020-03-10
    Sponsor Name:Oslo University Hospital
    Full Title: TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA...
    Medical condition: Central retinal artery occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Completed) FI (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005432-33 Sponsor Protocol Number: UX001-CL301 Start Date*: 2016-06-07
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion...
    Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka’s disease, or quadriceps sparing myopathy (QSM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075048 Hereditary inclusion body myopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006074-28 Sponsor Protocol Number: 0893-015 Start Date*: 2008-02-21
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Me...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DK (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004152-22 Sponsor Protocol Number: DEX-TRA-06 Start Date*: 2016-03-01
    Sponsor Name:MENARINI RICERCHE S.p.A.
    Full Title: Analgesic efficacy of oral dexketoprofen trometamol/tramadol hydrochloride versus tramadol hydrochloride/paracetamol: a randomised, double-blind, placebo and active-controlled, parallel group study...
    Medical condition: moderate to severe acute pain after removal of impacted lower third molar
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004867 10066714 Acute pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002567-24 Sponsor Protocol Number: M120204-063 Start Date*: 2005-04-04
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
    Medical condition: The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003510-41 Sponsor Protocol Number: 200163 Start Date*: 2014-01-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001095-77 Sponsor Protocol Number: AC4105211 Start Date*: 2008-09-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 form...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004505-14 Sponsor Protocol Number: Modic02 Start Date*: 2015-03-04
    Sponsor Name:Oslo University Hospital HF, Ullevål Hospital, FORMI-Formidlingsenheten for muskel- og skjelettlidelser
    Full Title: Antibiotic treatment in patients with chronic low back pain and Modic Changes: a double-blind randomized placebo-controlled trial
    Medical condition: A recent Danish study published during spring 2013 advances a remarkable cause and treatment with Amoxicillin for a selected sub-group of low back pain patients.The study was based upon a hypothesi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-003746-33 Sponsor Protocol Number: REVC006 Start Date*: 2020-09-30
    Sponsor Name:ReViral Ltd.
    Full Title: Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) ...
    Medical condition: Symptomatic RSV infection (upper airway involvement only) in subjects who have undergone HCT transplantation within 1 year of Randomization and who are moderately to severely immunocompromised.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10024970 Respiratory tract infections HLGT
    21.1 10021881 - Infections and infestations 10024968 Lower respiratory tract infection PT
    20.1 10021881 - Infections and infestations 10065188 Lower respiratory tract infection viral PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004235-77 Sponsor Protocol Number: XILO-FIST Start Date*: 2015-01-02
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST).
    Medical condition: Ischaemic stroke or transient ischaemic attack (TIA) (ICD Classification Code I63.0-9 and G45.0-1)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-001240-30 Sponsor Protocol Number: CL3-05702-013 Start Date*: 2006-10-31
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year in...
    Medical condition: Diabetes mellitus non insulino dependant
    Disease: Version SOC Term Classification Code Term Level
    9.0 10027433 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) LV (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) HU (Completed) SI (Prematurely Ended) AT (Prematurely Ended) GB (Completed) SK (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-001645-33 Sponsor Protocol Number: AC4115408 Start Date*: 2011-08-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: AC4115408: A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subje...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002537-15 Sponsor Protocol Number: R10933-10987-COV-2066 Start Date*: 2020-10-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    23.0 10021881 - Infections and infestations 10084510 Coronavirus infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004086-87 Sponsor Protocol Number: HZA107116 Start Date*: Information not available in EudraCT
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, double-blind, parallel group, multicenter, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily f...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) Outside EU/EEA LT (Completed) HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004055-20 Sponsor Protocol Number: ICR-CTSU/2013/10040 Start Date*: 2014-09-23
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.
    Medical condition: Castrate resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004905-29 Sponsor Protocol Number: CCSJ117A12201C Start Date*: 2020-12-28
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients ≥18 years of ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) BG (Prematurely Ended) FR (Completed) SK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002603-17 Sponsor Protocol Number: 1218.89 Start Date*: 2013-01-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin ...
    Medical condition: Type 2 diabetes patients receiving treatment with ACEi or ARB with micro- or macroalbuminuria (UACR between 30 and 3000 mg/g creatinine). [ACEi=Angiotensin Converting Enzyme inhibitor; ARB=Angioten...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005616-40 Sponsor Protocol Number: 0941-017 Start Date*: 2009-02-03
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabe...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IE (Completed) FI (Completed) EE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002580-13 Sponsor Protocol Number: LPA111834 Start Date*: 2009-05-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma
    Medical condition: Mild asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 23 22:10:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA